Novartis AG · SIX:NOVN
Novartis — Technical Presentation (November 2008)
17 slides from Novartis's technical presentation, Nov 19, 2008
Slide 1: The Discovery and Application of Effective Cancer Therapeutics
The Discovery and Application of Effective Cancer Therapeutics Research Day — November 19, 2008 William R. Sellers, M.D. Global Head of Oncology Research Novartis Institutes for BioMedical Research th NovarTIs Disclaimer These materials contain certain forward-looking statements relating to the Grou
Slide 2: Key messages
Key messages = The Novartis oncology early clinical pipeline is very robust. = Our focus is on delivering mechanism-based therapeutics to the right patients. * Examples: Glivec RAF 265 (BRAF inhibitor) BEZ235 (PI3K inhibitor) = Antibodies are key therapeutics in our pipeline. «Example: BHQ880 (anti-
Slide 3: Glivec: Illustrating the paradigm
Glivec: Illustrating the paradigm High Unmet Medical Need High Understanding of Disease Mechanism 5 | Research Day| November 19,2008 | Wiliam R. Sellers Ub Novartis Glivec: Illustrating the paradigm High Unmet Medical Need SS High Understanding of Disease Mechanism 5 | Research Day| November 19, 200
Slide 4: Glivec: Translation from CML to melanoma
Glivec: Translation from CML to melanoma Tissue biopsy Typically melanoma is classified by its microscopic appearance not by molecular measures. 6 | Research Day| November 19, 2008 | William R, Sellers Glivec: Translation from CML to melanoma A subset of melanoma tumors harbor mutations in KIT 7 | R
Slide 5: Glivec: Translation from CML to melanoma
Glivec: Translation from CML to melanoma A subset of melanoma tumors harbor mutations in KIT DNA analysis of melanoma tumors 7 | Research Day| November 19,2008 | Wiliam R, Sellers th Novartis Glivec: Translation from CML to melanoma Glivec is a robust inhibitex of the KIT kinase (nv @ | Research Day
Slide 6: Glivec: Translation from CML to melanoma
Glivec: Translation from CML to melanoma Glivec is a robust inhibitex of the KIT kinase @ | Research Day| November 19, 2008 | Wiliam R, Sellers th Novartis Glivec: Translation from CML to melanoma Major tumor regression in a KIT mutant melanoma patient DNA analysis of melanoma tumors 7 = —_ Glivec H
Slide 7: Glivec: Translation from CML to melanoma
Glivec: Translation from CML to melanoma Major tumor regression in a KIT mutant melanoma patient DNA analysis of melanoma tumors a — Glivec sy a” —— Hodi FS et ai. J Clin Oncol. 2008 26:2046-51 @ | Research Day| November 19, 2008 | Wiliam R. Sellers th Novartis RAF 265: Targeting BRAF in melanoma BR
Slide 8: RAF265: Targeting BRAF mutation
40 | Research Day| November 19, 2008 | William Ub Novartis RAF265: Targeting BRAF mutation. Ub Novartis
Slide 9: RAF 265: Targeting BRAF in melanoma
RAF 265: Targeting BRAF in melanoma Pre-clinical PET responses in BRAF mutant tumors PET scan respons PQeoou analysis of elanoma tumors Control RAF265 Ub Novartis RAF 265: Targeting BRAF in melanoma Clinical PET and CT response in BRAF mutant patient NA analysis of elanoma tumors <a» search Day| Nov
Slide 10: RAF 265: Targeting BRAF in melanoma
RAF 265: Targeting BRAF in melanoma Clinical PET and CT response in BRAF mutant patient Fe 0 analysis of elanoma tumors 42 | Research Day | November 19, 2008 | William R. Sellers th Novartis BEZ235: Targeting the PISK pathway PI3K mutations in a large fraction of breast and colon cancers Breast canc
Slide 11: BEZ235: Targeting the PI3K pathway
BEZ235: Targeting the PISK pathway PI3K mutations in a large fraction of breast and colon cancers Breast cancer Colorectal cancer 49 | Research Day| November 10,2008 | Wiliam R. Sellers tb Novartis BEZ235: Targeting the PISK pathway PI3K mutations in a large fraction of breast and colon cancers Brea
Slide 12: BEZ235: Targeting the PI3K pathway
BEZ235: Targeting the PI3K pathway PI3K mutation induces cancer in a mouse model 414 | Research Day| November 19, 2008 | Wiliam R. Sellers Mnyy, ) MMH Ub Novartis BEZ235: Targeting the PISK pathway BEZ235 targets both PI3K and mTOR — two-point inhibition 46 | Research Day November 19, 2008 | Wiliam
Slide 13: BEZ235: Targeting the PI3K pathway
BEZ235: Targeting the PISK pathway BEZ235 targets both PI3K and mTOR — two-point inhibition Pecan om 45 | Reseatch Day] November 19,2008 | Wiliam R, Sellets Ub Novartis BEZ235: Targeting the PISK pathway Complete regression of PI3K driven tumors in mice Ny My S\) " c MM BEZ235 46 | Research Day Nove
Slide 14: BEZ235: First-in-man clinical trials
BEZ235: Targeting the PISK pathway Complete regression of PI3K driven tumors in mice . BEZ235 er 19, 2008 | Wiliam R. S Ub Novartis BEZ235: First-in-man clinical trials Prolonged disease stabilization in some patients with mutations es [=] =) BEZ235 on [=] Oo Days without progression N oO oO 7 |Rese
Slide 15: BHQ880: First-in-class anti-DKK1 antibody
BHQ880: First-in-class anti-DKK1 antibody DKK1 overproduction in multiple myeloma induces bone lysis | Multiple Myeloma 48 | Research Day| November 10,2008 | Wiliam R. Sellers th Novartis BHQ880: First-in-class anti-DKK1 antibody BHQ880 blocks osteolysis in pre-clinical cancer models BHQ880 anti-DKK
Slide 16: BHQ880: First-in-class anti-DKK1 antibody
BHQ880: First-in-class anti-DKK1 antibody BHQ880 blocks osteolysis in pre-clinical cancer models BHQ880 anti-DKK1 Uh Novartis Translation of the genome to therapeutics works ...but in many cases we hit roadblocks Genome ws ) Human Disease 20 | Research Day| November 19,2008 | Willam R, Sellers th No
Slide 17: Translation of the genome to therapeutics works
Translation of the genome to therapeutics works ...but in many cases we hit roadblocks Genome alterations in cancer without targeted therapies Colorectal cancer APC Pancreas cancer RAS Lymphoma Myc Chronic leukemia BCL2 Prostate cancer ETV1 Human Disease 20 | Research Day| November 19,2008 | Wiliam